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Abstract Seasonality in the incidence and prevalence of gout
has previously been reported but the cause of this seasonality
in gout is not explained. The aim of this study was to evaluate
possible seasonal variations of urate in a large unselected
Swedish adult population. We analyzed 170,915 urate test
results from patients at a tertiary care hospital between 2000
and 2016. The results were divided according to sex and sam-
pling month of the year. The median urate values were overall
higher in males compared to females and both males and
females had peak urate concentrations in the summer months
(June–August). There is a seasonal pattern for urate concen-
trations in a large Swedish population similar to the previously
reported seasonality for gout. This may be clinically important
and could contribute to the circannual variation of gout. The
seasonal pattern should be recognized when evaluating patient
results both in clinical practice and in research studies.
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Introduction
Gout is one of the most commonly diagnosed rheumatic dis-
eases and it is estimated that the prevalence is 1–2% in an
adult population [1, 2]. Elderly individuals andmales are more
affected [2]. It is often recommended that the urate lowering
treatment of gout patients should be monitored by urate con-
centrations. The treatment goals are usually to reduce serum
urate <360 μmol/L (6 mg/dL) if the patient do not have tophi
and <300μmol/L (5 mg/dL) in patients with tophi [3–5]. Gout
is often divided into primary gout and secondary gout.
Secondary gout is more common and is mainly caused by life
style factors, pharmaceutical treatments or other diseases [6,
7]. The prevalence of gout has gradually increased over the
last decades [8]. This has been attributed to among other fac-
tors the increased life expectancy but also to the worldwide
increase in obesity and increased body mass index (BMI) [9].
Alcohol intake may also increase urate production and reduce
the elimination while diuretics such as thiazides and acetylic
acid may reduce the elimination of urate [10, 11].
Urate or uric acid is a metabolite from the purine degrada-
tion and is ubiquitous in humans. It is the major determinant of
the urate concentration [12]. Humans have a limited capacity to
degrade urate and the elimination is mainly through the kidneys
or the gastrointestinal tract [13]. Increased levels of urate can
consequently either be due to increased synthesis or decreased
elimination of urate. When blood and tissues become
oversaturated with uric acid, crystallization will occur [14,
15]. The crystallization occur in tissues and may cause flares
of inflammation in predominantly joints, bursas, tendon
sheaths and surrounding soft tissues. Although, hyperuricemia
is the single most important risk factor for gout, only a minority
of patients with hyperuricemia develop gout. The association
between urate concentrations and gout is thus complex.
Nevertheless, measuring the urate concentration is crucial for
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diagnosing and monitoring of patients with gout and it is thus
important to be aware of natural fluctuations of urate in the
population.
The aim of this study was to identify possible seasonal
variations in plasma urate and, if so, describe the seasonal
pattern. We also aimed to correlate the seasonal variation of
urate with the previously reported seasonality of gout with
higher incidence during the summer period in countries locat-
ed in the northern hemisphere [16, 17].
Methods
Samples
All urate samples between May 15th, 2000, and December 31st,
2015, analyzed at the central lab in the Uppsala University
Hospital, Uppsala, Sweden, in Uppsala County, Sweden, were
recorded in the laboratory information system (FlexLab). All
tests were performed on fresh blood samples and only test reports
with a valid quantitative result and information on age and sex
were included in further analyses. In total, 170,915 test results
were included. The studywas approved by the local ethical board
(01–367) and complied with the World Medical Association
Declaration of Helsinki regarding ethical conduct of research.
Statistical analysis
The difference between males and females was tested with
Mann-Whitney U test. Differences between calendar months
were tested with Kruskal-Wallis ANOVA. The results were
reported for men and women separately. A p value of <0.05
was considered as significant.
Results
Urate values in males and females
A total of 170,915 urate test results (80,050 samples frommales
and 90,865 from females) were collected. The median urate
concentration for the males was 377 μmol/L (Interquartile range
(IQR) 303–462 μmol/L) and for the females 294 μmol/L (IQR
232–374 μmol/L). There were significantly higher median con-
centrations in males compared to women (p < 0.00001).
Seasonal variation of urate
Urate concentrations were significantly different between the
calendar months in both men (P < 0.0001) and women
(P < 0.0001) with the highest concentrations during the sum-
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Fig. 1 Median and interquartile ranges for urate values in μmol/L for males divided according to month (P < 0.0001)
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June–August were significantly higher in both men and wom-
en when each month was compared.
Discussion
Gout is the most common inflammatory arthritis associated
with crystal formation. The deposition of urate crystals is a
consequence of supersaturated levels of soluble urate in com-
bination with local factors that may modify the crystal forma-
tion. The point of saturation of urate in plasma is considered to
be approximately 6.8 mg/dl (405 μmol/L) [15]. The aim of
urate lowering therapies is to reduce the urate level below the
point of saturation in order to prevent gout flares and symp-
toms. Most recommendations aim to reduce urate <360 μmol/
L (6 mg/dL) to hinder the formation of new urate crystals [18].
In patients with tophi a limit of <300 μmol/L (5 mg/dL) [19].
The present study shows a clinically important seasonal vari-
ation for plasma urate. The median urate levels in July are
approximately 20 μmol/L higher than the median urate levels
in February and the upper quartile approximately 30 μmol/L
higher with similar patterns for both gender. In our opinion the
seasonal variation should be taken into account when
reviewing urate test results and a lower treatment threshold
should be used in February in comparison with in July.
Additionally, if a patient has urate concentration of
350 μmol/L in the beginning of the year, it is likely that the
urate levels may exceed 360 μmol/L during the summer
months. Consequently, a more intensive urate lowering thera-
py may be applied during the summer as well.
The increased levels of urate seen during the summer
months and the smaller peak observed around December–
January may be due to variation in the diet. The traditional
Christmas-New year celebrations in Sweden are usually asso-
ciated with increased consumption of food rich in meat, alco-
hol, and beer. Studies have shown that the holiday season is a
critical period for weight gain as an effect of the increased
food intake [20]. High meat consumption and alcohol intake
especially beer is known to be risk factors for gout. The warm
weather during the summer months is associated with in-
creased intake of sweetened beverages and fruits. Studies have
shown that fructose intake from sugar-sweetened beverages
causes transient increases in plasma urate [21]. Other dietary
factors are seafood, coffee, and dairy product consumption.
Even if Sweden in general has a high coffee consumption, we
do not know of any seasonal variation that could be related to
increased urate levels during the summer months.
The seasonal urate variation with high levels during the sum-
mer months is in agreement with two previous studies on gout
incidence from the northern hemisphere [16, 17] but contradic-
tory to a US study [22]. The UK and Korea studies show higher
gout incidence during the same time of the year. Considering
that hyperuricemia is the strongest risk factor for gout, it seems
reasonable that the higher urate levels during the summer
months may contribute to the higher incidence of gout. This
would also implicate that a reduction of urate levels during the
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Fig. 2 Median and interquartile urate values in μmol/L for females di-
vided according to month (P < 0.0001)
Table 1 Urate values for individual months for females and males,
respectively. The values are presented as min, first quartile, median,
third quartile, and max values
Min First quartile Median Third quartile Max
Females
January 15 231 292 370 1303
February 6 224 288 367 1580
March 10 226 287 369 1587
April 6 234 295 372 1356
May 8 236 298 374 1164
June 9 239 302 383 1554
July 6 240 308 397 1423
August 10 238 301 382 1244
September 6 234 296 372 1535
October 7 232 292 368 1634
November 26 228 289 370 1305
December 8 228 292 373 1317
Males
January 5 302 376 460 1467
February 5 297 367 451 1172
March 6 300 375 460 1130
April 11 306 381 468 1252
May 8 309 383 462 1404
June 5 314 391 478 1334
July 6 310 393 481 1313
August 7 312 387 475 1420
September 6 303 375 458 1738
October 14 296 368 448 1856
November 5 297 371 454 1385
December 5 300 372 458 1410
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during the same time period. For patients using urate lowering
therapies, such as allopurinol, higher doses might be needed
during the summer time. Although the increased levels of urate
were consistently observed during the summer, the current study
was not designed to determine the cause to this finding. Neither
was the study designed to firmly associate the increased levels
with the incidence of gout. The clinical reason for obtaining the
urate samples was not available. Although the urate samples
were likely obtained in similar clinical situations, we cannot rule
out that the circannual higher incidence of gout during summer
may have affected the causes for heightened urate concentration.
Nonetheless, the amount of samples greatly exceeds the clinical
manifestations of gout in the current population, and hence,
median plasma urate is hardly changed by increased gout inci-
dence and, consequently, urate are likely obtained in far more
clinical situations than only to diagnose possible gout. Reduced
glomerular filtration rate leads to increased urate levels. Further
studies are warranted that focus on the seasonal variation of
urate in patients with reduced GFR levels.
In conclusion, urate shows a clear seasonal variation with
higher levels during the summer months which coincides with
the seasonal variation previously reported for gout. This sea-
sonal urate variation should be taken into account when mon-
itoring gout patients.
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